Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle (Placebo) applied BID Clear all
Completed Phase 4 Interventional Results available

Combination Therapy for Atopic Dermatitis

NCT00119158
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Combination of pimecrolimus and fluticasone, pimecrolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

NCT00820950
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 1 Interventional

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

NCT01702181
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OPA-15406, Tacrolimus, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Mobile, Alabama • Hot Springs, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel

NCT01844739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NVN1000 4% Gel, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

NCT01123772
View directory record Official record
Conditions
Health
Interventions
INO-8875, Placebo control
Drug · Other
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
35 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 25, 2026, 6:00 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

NCT06400511
View directory record Official record
Conditions
Blepharitis
Interventions
Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment
Drug
Lead sponsor
Famy Life Sciences, a Viatris Company
Industry
Eligibility
2 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
29
States / cities
Pheonix, Arizona • Garden Grove, California • Glendale, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

NCT04313400
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2
Drug
Lead sponsor
Amytrx Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Cerritos, California • Encino, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Halobetasol Propionate Lotion 0.05%, Placebo
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 25, 2026, 6:00 PM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

NCT04769648
View directory record Official record
Conditions
Ocular Graft-versus-host Disease
Interventions
Pro-ocular™ Topical Gel 1%, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 25, 2026, 6:00 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

NCT06189638
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Antimicrobial Peptide PL-5 Topical Spray and Placebo
Drug
Lead sponsor
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Vista, California • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

NCT03850483
View directory record Official record
Conditions
Psoriasis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

NCT04135560
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
PF-07038124 and Vehicle, PF-07038124 or vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

NCT03680131
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0%
Drug
Lead sponsor
Edesa Biotech Inc.
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
14
States / cities
Long Beach, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 2 Interventional

Three-Arm Trial of Novel Treatment for Tinea Pedis

NCT03135912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride
Drug
Lead sponsor
South End Skin Care
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03028363
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
9 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
38
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Results available

Eyelid Androgen Treatment in Dry Eye

NCT06154200
View directory record Official record
Conditions
Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Interventions
Testosterone gel 4.5%, Vehicle gel
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss

NCT04450589
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 25, 2026, 6:00 PM EDT
Recruiting Phase 1 Interventional

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

NCT06504160
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Results available

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

NCT00847912
View directory record Official record
Conditions
Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions
5-fluorouracil, Placebo, vehicle control
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

NCT04921969
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

NCT03903822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 25, 2026, 6:00 PM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 25, 2026, 6:00 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 25, 2026, 6:00 PM EDT